NN Petrov Research Institute of Oncology

Saint Petersburg 197758

1 studies enrolling now · 11 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Known or Suspected Focal Liver Lesions, Metastatic Nonsquamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer, Neoplasm Metastasis, Non-small Cell Lung Cancer, Refractory Metastatic Gastric Cancer, Severe Renal Impairment, Solid Tumors

Studies at this site

• The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials — Recruiting now
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer — Completed
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Running, not enrolling
• Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function — Completed
• Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer — Completed
• E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer — Completed
• Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma — Stopped early